Comparison of Efficacy of Oral Fluconazole Versus Oral Itraconazole in the Treatment of Pityriasis Versicolor
NCT ID: NCT06922344
Last Updated: 2025-04-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE4
106 participants
INTERVENTIONAL
2025-03-01
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparing the Efficacy of Oral Fluconazole Versus Oral Itraconazole in Treating Resistant Tinea Corporis
NCT07342153
An Open-label, Two-period, Fixed-sequence Study to Evaluate Multiple-dose Itraconazole Effect on The Single-dose PK of PF-06372865 in Healthy Subjects
NCT02475746
A Study To Evaluate The Effect Of Itraconazole On Pharmacokinetics Of PF-06463922 In Healthy Volunteers
NCT02838264
Role of Oral Voriconazole in the Treatment of Resistant Dermatophyte Infections
NCT06680544
A Study of Itraconazole in the Management of Superficial Fungal Infections in India
NCT03923010
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group A, Fluconazole group
Group A consists of patients in whom oral fluconazole is given in dose of 300mg once weekly for 2 weeks.
Fluconazole
Oral fluconazole prescribed to group A
Group B, Itraconazole group
Group B consists of patients in whom oral Itraconazole is given in dose of 100mg Twice for 5 days.
Itraconazole
Oral itraconazole prescribed to Group B
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Fluconazole
Oral fluconazole prescribed to group A
Itraconazole
Oral itraconazole prescribed to Group B
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Patients who received any anti-fungal therapy in the last one month.
* Pregnant or lactating women.
18 Years
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Khyber Teaching Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hajira Amin
Doctor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Khyber Teaching Hospital
Peshawar, KPK, Pakistan
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
84/DME/KMC
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.